

Potential Sources of Clinically Compatible Human Pluripotent Stem Cell Lines

Any applicant who intends to develop an allogeneic human pluripotent stem cell (hPSC)-derived therapeutic with CIRM funding must establish evidence of disease/injury modifying activity using a **clinically compatible** cell source that can be translated for clinical use. An applicant should plan to select a clinically compatible hPSC line to establish this data during the course of a DISC2 award or must have already established this data if applying for TRAN1 or CLIN1.

To be considered **clinically compatible**, a therapeutic candidate that is to be composed of or manufactured from donor cells or tissues *must* meet the following requirements:

- Cells meet the Good Tissue Practices (GTP) requirements for donor eligibility, or there is plan in place to address GTP; and
- Cell source (tissue or cell line) has been appropriately consented by donor for intended use and for clinical development and sale.

CIRM is providing a list of hPSC lines that, to the best of our knowledge, could potentially meet the definition of clinically compatible. This table will be periodically updated as more CIRM Resource Partners are onboarded or as CIRM becomes aware of hPSC line providers.

Provider	hPSC	Line Name(s)	CIRM Resource Partner*
AgeX	hESC	ESI-017, ESI-035, ESI-049, ESI-051, ESI-053	N
Allele	iPSC	Multiple off-the-shelf lines, custom manufacturing services	N
CiRA Foundation	iPSC	Enquire with provider	N
ElevateBio	iPSC	Enquire with provider	Y (contact bd@cirm.ca.gov)
Fujifilm CDI	iPSC	Enquire with provider	N
Hadassah hESC Research Center	hESC	HAD-C 100, HAD-C 102, HAD-C 106	N
I Peace, Inc.	iPSC	Multiple off-the-shelf lines, custom manufacturing services, and GMP-grade media	N
Novo Nordisk	hESC	Novo Nordisk hESC line	Y (contact bd@cirm.ca.gov)
Reprocell	iPSC	Multiple off-the-shelf lines, custom manufacturing services	N
Sampled	iPSC	LiPSC-GR1.1	N
WiCELL	hESC	WA01, WA07, WA09, WA14 (AKA H1, H7, H9, H14)	N

***CIRM Industry Resource Partner:** The indicated organization has worked with CIRM to provide CIRM researchers with access to its clinically compatible hPSC line(s) under a standard agreement. CIRM does not endorse nor require the use of CIRM Industry Resource Partners. Please contact bd@cirm.ca.gov for additional information on CIRM Resource Partner hPSC lines, pricing and agreement templates.

CIRM Disclaimer: The information in the table has been collected by CIRM to help CIRM awardees accelerate the development of pluripotent stem cell-derived therapeutics. The information is intended to be provided in an unbiased way and is not an endorsement of any specific vendor. CIRM awardees are not required to utilize any vendors in the list above. The accuracy of the information listed is not guaranteed to be current by CIRM. It is the CIRM awardee's responsibility to ensure that the hPSC lines meet CIRM award requirements as well as any other regulatory or legal requirements. Please contact the individual vendors to verify any information listed in this Table.